CARB-X announced the investment of first grants to two German research teams from the German Helmholtz Centre for Infection Research that are developing novel…
Researchers from the Helmholtz Centre for Infection Research (HZI) and the Lead Discovery Center GmbH (LDC) could receive up to US$8.77 million from CARB-X…
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) team could receive up to US$6.31 million if all milestones are successfully met CARB-X is awarding…
Single intravenous dose Phase 1 study in healthy volunteers showed that EBL-1003 (apramycin) was safe and well tolerated in all dose groups. The results…
High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors and ensure the availability of important medicines for…
The Global AMR R&D Hub publishes its first report “The state of public and philanthropic investments in AMR R&D – The 2020 annual report…
The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign. The content is available online and a printed publication will shortly be…
BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii BioVersyshas reached a major milestone by entering clinical…
CARB-X announced today it is awarding up to US$2.62 million to Polyphor AG (SIX:POLN), headquartered in Allschwil, Switzerland, to develop a new antibiotic to…
